William Blair & Company
CLYM

William Blair & Company’s Climb Bio CLYM Stock Holding History

William Blair & Company’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
12,700
+700
+6% +$7.23K ﹤0.01% 1607
2026
Q1 		$82.2K Buy
12,000
+1,000
+9% +$5.77K ﹤0.01% 1623
2025
Q4 		$44K Buy
+11,000
New +$26.4K ﹤0.01% 1666

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

William Blair & Company's CLYM Position: Q2 2026 in Review

William Blair & Company increased its Climb Bio (CLYM) stake by 5.8% in Q2 2026, buying an estimated $7.23K and bringing the position to 12,700 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

William Blair & Company first reported a position in CLYM in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • William Blair & Company held 12,700 shares of Climb Bio worth $166K as of Q2 2026.
  • William Blair & Company bought 700 Climb Bio shares in Q2 2026, an estimated $7.23K.
  • Climb Bio made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1607 holding.
  • William Blair & Company first reported a position in Climb Bio in Q4 2025 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.